tgDCC-E1A gene therapy (Targeted Genetics)

N/A

Report date: 2022/10/14 20:00:43

Base Information

Drug NametgDCC-E1A gene therapy (Targeted Genetics)
Drug Alias NameHER-2/neu inhibitorRGG 0853LF 160519E1A gene therapy
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsHead and Neck NeoplasmsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTargeted Genetics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of PittsburghThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsHead and Neck NeoplasmsOvarian Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A